OliX Pharmaceuticals,Inc
KOSDAQ 226950.KQ
OliX Pharmaceuticals,Inc Price to Book Ratio (P/B) on January 14, 2025: 4.86
-
OliX Pharmaceuticals,Inc 52-week high Price to Book Ratio (P/B) is 9.77 on October 23, 2024, which is 100.96% above the current Price to Book Ratio (P/B).
-
OliX Pharmaceuticals,Inc 52-week low Price to Book Ratio (P/B) is 2.72 on June 28, 2024, which is -44.08% below the current Price to Book Ratio (P/B).
-
OliX Pharmaceuticals,Inc average Price to Book Ratio (P/B) for the last 52 weeks is 5.18.
| Date | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield | Price to Earnings Ratio (P/E) |
|---|
| CEO | Mr. Dong-Ki Lee Ph.D. |
| IPO Date | July 18, 2018 |
| Location | South Korea |
| Headquarters | #1014 Gwanggyo Ace Tower1, 17 |
| Employees | 72 |
| Sector | Health Care |
| Industries | |
OliX Pharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101 for skin scar; OLX102 for skin whitening; OLX103, an atopic dermatitis product; OLX104 for hair loss; OLX105, an anti-wrinkle product; and OLX106 for diabetic foot ulcer. Its products pipeline also comprise OLX301 for age-related macular degeneration retinal fibrosis; OLX304 for retinitis pigmentosa; OLX201 for lung fibrosis; OLX202 for asthma; OLX203 for influenza; OLX401 for neuropathic pain; OLX701 for liver fibrosis; and OLX701 for cancer immunotherapy. The company has a collaboration agreement with Théa to develop SiRNA therapeutics for ophthalmic diseases; and a research collaboration with PCI Biotech Holding ASA. OliX Pharmaceuticals, Inc. was founded in 2010 and is based in Suwon, South Korea.
Past 5 years
USD 83.61
USD 80.54
USD 108.37
USD 21.07
USD 17.25
StockViz Staff
January 15, 2025
Any question? Send us an email